Tag: mCRC

Targeted therapy regimen, BRAFTOVI® (encorafenib) in combination with cetuximab, included on MOH Cancer Drug List, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer who have received prior systemic therapy. BRAFTOVI in combination with cetuximab has been included on MOH CDL, for patients with BRAFV600E-mutant metastatic colorectal cancer…

PRINCETON, N.J.–(BUSINESS WIRE)–   Bristol Myers Squibb Company Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -8HW trial evaluating…

Colorectal Cancer: © peterschreiber.media – stock.adobe.com The combination of nivolumab (Opdivo) with ipilimumab (Yervoy) as a first-line treatment for patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) vs investigator’s choice of chemotherapy in the…

Sampling sites and depths Metagenomes were produced from sediment samples at drilling sites U1545B to U1549B that follow a northwest-to-southeast transect across the northwestern flanking region of Guaymas Basin (Fig. 1A) and include an off-axis hydrothermal system, the Ringvent site (Fig. 1B). The samples were selected to coordinate with depths used for…

Findings from the primary analysis of the phase 3 CodeBreaK 300 trial (NCT05198934) revealed that the combination of sotorasib (Lumakras) at 960 and 240 mg with intravenous (IV) panitumumab (Vectibix) improved progression-free survival (PFS) vs standard-of-care (SOC) in patients with chemorefractory, KRAS G12C-mutated, metastatic colorectal cancer (mCRC).1 With a median…

FDA Approves Fruquintinib for Patients With Pretreated Metastatic Colorectal Cancer Fruquintinib (Fruzaqla), an oral therapy, is now approved to treat adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.1 The FDA approval…

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…

The combination of pembrolizumab (KEYTRUDA), an anti-PD-1 therapy, plus lenvatinib (LENVIMA), a multiple-receptor tyrosine kinase inhibitor, failed to meet its primary end point of overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in a recent phase 3 trial. Moreover, the drugs’ manufacturers announced that they discontinued the phase…

Background Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3, was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated…

This approval of trifluridine and tipiracil was based on findings from the phase 3 SUNLIGHT study (NCT04737187). The basis of this approval comes from positive findings from the phase 3 SUNLIGHT trial (NCT04737187) of trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin) vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer (mCRC)….

FDA Approves Trifluridine/Tipiracil With Bevacizumab For Metastatic Colorectal Cancer The FDA approved trifluridine and tipiracil (Lonsurf) plus bevacizumab as a treatment for patients with metastatic colorectal cancer (mCRC) who have already received treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and—for those with RAS wild-type disease—an anti-EGFR therapy….

Background Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (Bev) demonstrated promising efficacy in a randomized phase 2 trial of heavily pretreated patients (pts) with metastatic colorectal cancer (mCRC). SUNLIGHT was conducted to confirm these findings. Methods The global phase 3 SUNLIGHT study enrolled pts aged ≥18 years with histologically confirmed mCRC, ECOG PS…

During an Around the Practice® program hosted by CancerNetwork®, a panel of experts discussed key treatment updates including testing for and treatment of metastatic colorectal cancer (CRC). They reviewed these updates in the context of the treatment landscape and how they might impact clinical practice. The discussion was led by…

Amgen has shared positive results from a late-stage study evaluating its KRAS inhibitor, Lumakras (sotorasib), in certain lung cancer patients. The phase 3 CodeBreaK 200 trial compared Lumakras to docetaxel chemotherapy in patients with previously treated, locally advanced and unresectable or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). New data…

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, medical oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study (NCT05253651). In the global, open label, randomized, study,…

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif., May 31, 2023–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the…

Expert oncologists review key updates regarding metastatic colorectal cancer from recent meetings and discuss their implications on real-world clinical practice. At a recent Around the Practice program hosted by CancerNetwork®, experts discussed the use of molecular and genetic testing to better treat patients with metastatic colorectal cancer (CRC). The panel…

MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides a fourth quarter 2022 business update and an outlook for 2023. Michel Lussier, interim Chief Executive Officer…

The following is a summary of “Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance),” published in the January 2023 issue of Oncology by Raghav, et al. In metastatic colorectal cancer (mCRC), acquired genomic alterations (Acq-GAs), including RAS,…

Adding bevacizumab (Avastin) to trifluridine (FTD)/tipiracil (TPI; Lonsurf) yielded improvements in survival and disease control rates (DCRs) among patients with metastatic colorectal cancer (mCRC), according to according to results from the phase 3 SUNLIGHT study (NCT0437187). The survival benefit was consistent across all clinically relevant subgroups, and showed that the…

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design elements of clinical trials for biosimilar drugs are rigorous Evidence Rating Level: 1 (Excellent) Study Rundown: Biologic treatments constitute a large portion of prescription costs in the United States. Biosimilar…

Dr. Lenz on the Rationale for the CheckMate 9X8 in Metastatic CRC Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer. Heinz-Josef Lenz, MD, FACP, associate director, Clinical Research, J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director, University of Southern…

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

“…ctDNA may be more comprehensive representation of the tumor mutations of an individual patient,” the authors explained. “Longitudinal ctDNA analysis can also provide a molecular profile of how a tumor evolves and changes over time in response to chemotherapy.” They evaluated how the results of ctDNA analysis were associated with…